RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS
Clinical trials for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dual-target CAR-T therapy takes on hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…
Matched conditions: RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New dual-target CAR-T therapy takes on hard-to-treat plasma cell cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR BCMA-CD70 CAR-T for people with high-risk plasma cell neoplasms, a type of blood cancer. The therapy uses the patient's own immune cells, modified to target two cancer markers (BCMA and CD70), to attack the disease. The main…
Matched conditions: RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC